About Voltage-gated potassium channel subunit beta-3
Voltage-gated potassium channel subunit beta-3 (KCNAB3) is a protein
from Homo sapiens identified by UniProt accession
O43448, 404 residues long.
MolForge cross-references it against 0 known binders and
25 disease associations.
Target properties
| Protein name | Voltage-gated potassium channel subunit beta-3 |
| UniProt accession | O43448 |
| Gene | KCNAB3 |
| Organism | Homo sapiens |
| Length | 404 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (25)
Diseases linked to this target (Open Targets).
- neurodegenerative disease · score 0.49
- macula measurement · score 0.13
- gastric adenocarcinoma · score 0.10
- refractive error measurement · score 0.09
- refractive error · score 0.08
- smoking status measurement · score 0.07
- prostate carcinoma · score 0.04
- colorectal adenocarcinoma · score 0.04
- bilirubin measurement · score 0.03
- dilated cardiomyopathy 1I · score 0.03
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-O43448-F1 | alphafold | PREDICTED | 84.48 | — |
Amino-acid sequence (404 residues)
MQVSIACTEQ NLRSRSSEDR LCGPRPGPGG GNGGPAGGGH GNPPGGGGSG PKARAALVPR PPAPAGALRE STGRGTGMKY RNLGKSGLRV SCLGLGTWVT FGSQISDETA EDVLTVAYEH GVNLFDTAEV YAAGKAERTL GNILKSKGWR RSSYVITTKI FWGGQAETER GLSRKHIIEG LRGSLERLQL GYVDIVFANR SDPNCPMEEI VRAMTYVINQ GLALYWGTSR WGAAEIMEAY SMARQFNLIP PVCEQAEHHL FQREKVEMQL PELYHKIGVG SVTWYPLACG LITSKYDGRV PDTCRASIKG YQWLKDKVQS EDGKKQQAKV MDLLPVAHQL GCTVAQLAIA WCLRSEGVSS VLLGVSSAEQ LIEHLGALQV LSQLTPQTVM EIDGLLGNKP HSKK
Explore Voltage-gated potassium channel subunit beta-3 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets